<?xml version="1.0" encoding="UTF-8"?>
<p id="Par48">The potential drug–disease interactions in patients with COVID-19 have become a highly researched topic
 <sup>
  <xref ref-type="bibr" rid="CR12">12</xref>–
  <xref ref-type="bibr" rid="CR14">14</xref>
 </sup> (Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>). First, whether antihypertensive agents such as ACE inhibitors and angiotensin II receptor blockers (ARBs) are involved in the progression or prevention of COVID-19 is unknown
 <sup>
  <xref ref-type="bibr" rid="CR113">113</xref>,
  <xref ref-type="bibr" rid="CR119">119</xref>
 </sup>. Second, some of the potential antiviral drugs used to treat patients with COVID-19 are known to induce cardiotoxicity
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>
 </sup>.
</p>
